Overview

Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure

Status:
Completed
Trial end date:
2018-12-30
Target enrollment:
0
Participant gender:
All
Summary
A number of 100 patients with pulmonary hypertension associated with the left Heart failure scheduled for elective pulmonary arterial denervation (PADN) are randomized 1:1 to either PADN or control group.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
The First Affiliated Hospital with Nanjing Medical University
Treatments:
Angiotensin-Converting Enzyme Inhibitors
Digoxin
Diuretics
Mineralocorticoid Receptor Antagonists
Criteria
Inclusion Criteria:

- Age>18yr

- "Reactive"Pulmonary Hypertension in Left Heart Failure: mPAPā‰„25 mmHg, PCWP>15 mmHg and
pulmonary vascular resistance (PVR) [The PVR =(mPAP-PCWP)/ carbon monoxide]>3.0 woods
unit

- Voluntary acceptance of all follow-up assessment of program requirements.

Exclusion Criteria:

- WHO group I, III, IV, V pulmonary artery hypertension

- Severe Renal dysfunction (Ccr<30 ml/min)

- Blood platelet count<100,000/L

- Expected life span<12-month

- In pregnancy

- Systematical inflammation

- Malignant cancer(s)

- Tricuspid valve stenosis, Supra-pulmonary valve stenosis

- Allergic to studied drugs or metal materials